Oncology
Advanced Melanoma
4
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Advanced Melanoma is an early-stage landscape with 4 programs across 3 companies. The most active players are EMD Serono, Bristol-Myers Squibb, Sanofi.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
3programs
Small molecule133%
Monoclonal antibody133%
Protein / enzyme133%
Modality classified for 75% of 4 pipeline programs.
Analysis
Trial Status
2
clinical trials
Active, not recruiting2 · 100%
Clinical Trials
Trial Activity
Profiling and Reversing Metabolic Insufficiency in the Tumor Microenvironment in Advanced Melanoma: A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
Active, not recruiting·—·Phase 1·NCT03311308·23 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)